Company news
Biotron Limited (ASX:BIT) news
Biotron Limited news releases on 6ix. Latest, Sep 14, 2026: Resignation of Managing Director and Appendix 3Z
Press releases & updates
Resignation of Managing Director and Appendix 3Z
September 13, 2026
Sedarex First Milestone Met
July 12, 2026
$525K R&D Rebate Received
June 3, 2026
Hepatitis B Virus Program Update
March 17, 2026
Half Yearly Report and Accounts
February 26, 2026
Successful Issue of the Entitlement Offer Shortfall
January 29, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 28, 2026
Security Class Reinstatement to Quotation - BITO
December 21, 2025
Rights Issue Close
December 19, 2025
Security Class Suspension from Quotation - BITO
December 14, 2025
Non-Renounceable rights Issue Prospectus
November 18, 2025
Acquisition of Sedarex Limited and $2.5m capital raising
October 15, 2025
Trading Halt
October 12, 2025
Pause in Trading
October 12, 2025
Full Year Statutory Accounts and Appendix 4E
August 27, 2025
Rights Issue Closed
April 7, 2025
Replacement Prospectus
March 12, 2025
Response to ASX Query Letter
March 12, 2025
Supplementary Prospectus
March 4, 2025
Response to ASX Aware Query
March 3, 2025
Prospectus
March 2, 2025
Renounceable Rights Issue
February 27, 2025
Updated Appendix 4C
February 3, 2025
Agreement with C14 Consulting Group
November 26, 2024
$1.8M R&D Rebate Received
October 13, 2024
BIT225-012 PHASE 2 COVID-19 CLINICAL TRIAL
September 5, 2024
BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives
June 19, 2024
POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV
April 4, 2024
Response to ASX Price Query
March 26, 2024
COMPLETION OF PHASE 2 COVID CLINICAL TRIAL
August 16, 2023
Second Site Approved for Phase 2 Covid-19 Trial
May 12, 2023
Commencement Phase 2 Covid-19 Clinical Trial
May 3, 2023
Completion of Phase 2 HIV-1 Clinical Trials
March 8, 2023
International Presentation of BIT225 COVID-19 Data
February 20, 2023
$1.43M R&D rebate received
November 18, 2022
Commencement of Rights Trading - BITRC
October 31, 2022
Renounceable Issue
October 26, 2022
Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
October 3, 2022
Bit225 Covid-19 Human Study Commenced
September 13, 2022
BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
August 23, 2022
POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM
May 30, 2022
BIT225 EFFECTIVE AGAINST ESTABLISHED SARS-CoV-2 IN ANIMALS
May 2, 2022
Quarterly Cash Flow Report Appendix 4C
April 26, 2022
Quarterly Activities Report
April 26, 2022
$1.56M R&D Rebate Received
April 5, 2022
BIT225 Effectiveness Against COVID-19 in Animals
March 17, 2022
Quarterly Appendix 4C Cash Flow Report
January 27, 2022
BIOTRON DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALS
November 24, 2021
COMMENCEMENT OF TWO PIVOTAL BIT225 CLINICAL TRIALS
November 1, 2021
Quarterly Cash Flow Report
October 27, 2021